nach oben

Journal of Neural Transmission

Erschienen in:

29.06.2019 | Neurology and Preclinical Neurological Studies - Review Article

Sleep–wake and circadian disturbances in Parkinson disease: a short clinical guide

verfasst von: Christian R. Baumann

Erschienen in: Journal of Neural Transmission | Ausgabe 7/2019

Einloggen, um Zugang zu erhalten

Abstract

Sleep–wake and circadian disturbances are very frequent and often troublesome symptoms in patients suffering from Parkinson disease. Therefore, a concept for the evaluation and therapy of such disturbances must be considered and implemented by all physicians involved in Parkinson care. The present review shall offer a short and condensed guide for the clinician. It summarizes the epidemiology of sleep–wake and circadian disturbances in Parkinson disease, sheds some light into translational studies forwarding knowledge about underlying pathophysiological concepts, and discusses diagnostic approaches and current therapeutic recommendations, albeit the latter being mostly based on insufficient evidence. As most treatments for Parkinson-related sleep–wake disturbances are still off-label, we need more prospective randomized trials for being able to optimize and personalize treatment for every single patient.

Amara AW, Chahine LM, Videnovic A (2017) Treatment of sleep dysfunction in Parkinson’s disease. Curr Treat Options Neurol 19(7):26PubMedPubMedCentralCrossRef

Bassetti CL, Bargiotas P (2018) REM Sleep Behavior Disorder. Front Neurol Neurosci 41:104–116PubMedCrossRef

Baumann-Vogel H, Imbach LL, Sürücü O, Stieglitz L, Waldvogel D, Baumann CR, Werth E (2017) The impact of subthalamic deep brain stimulation on sleep-wake behavior: a prospective electrophysiological study in 50 Parkinson patients. Sleep. https://doi.org/10.1093/sleep/zsx033 PubMedCrossRef

Bliwise DL, Trotti LM, Juncos JJ, Factor SA, Freeman A, Rye DB (2013) Daytime REM sleep in Parkinson’s disease. Parkinsonism Relat Disord 19(1):101–103PubMedCrossRef

Breen DP, Williams-Gray CH, Mason SL, Foltynie T, Barker RA (2013) Excessive daytime sleepiness and its risk factors in incident Parkinson’s disease. J Neurol Neurosurg Psychiatry 84(2):233–234PubMedCrossRef

Breen DP, Vuono R, Nawarathna U, Fisher K, Shneerson JM, Reddy AB, Barker RA (2014) Sleep and circadian rhythm regulation in early Parkinson disease. JAMA Neurol 71(5):589–595PubMedPubMedCentralCrossRef

Büchele F, Hackius M, Schreglmann SR, Omlor W, Werth E, Maric A, Imbach LL, Hägele-Link S, Waldvogel D, Baumann CR (2018) Sodium oxybate for excessive daytime sleepiness and sleep disturbance in parkinson disease: a randomized clinical trial. JAMA Neurol 75(1):114–118PubMedCrossRef

Chahine LM, Ahmed A, Sun Z (2011) Effects of STN DBS for Parkinson’s disease on restless legs syndrome and other sleep-related measures. Parkinsonism Relat Disord 17(3):208–211PubMedCrossRef

Chahine LM, Amara AW, Videnovic A (2017) A systematic review of the literature on disorders of sleep and wakefulness in Parkinson’s disease from 2005 to 2015. Sleep Med Rev 35:33–50PubMedCrossRef

Chiaro G, Calandra-Buonaura G, Cecere A, Mignani F, Sambati L, Loddo G, Cortelli P, Provini F (2018) REM sleep behavior disorder, autonomic dysfunction and synuclein-related neurodegeneration: where do we stand? Clin Auton Res 28(6):519–533PubMedCrossRef

De Cock VC, Vidailhet M, Leu S, Texeira A, Apartis E, Elbaz A, Roze E, Willer JC, Derenne JP, Agid Y, Arnulf I (2007) Restoration of normal motor control in Parkinson’s disease during REM sleep. Brain 130(Pt 2):450–456PubMedCrossRef

De Cock VC, Bayard S, Jaussent I, Charif M, Grini M, Langenier MC, Yu H, Lopez R, Geny C, Carlander B, Dauvilliers Y (2014) Daytime sleepiness in Parkinson’s disease: a reappraisal. PLoS ONE 9(9):e107278CrossRef

De Pablo-Fernández E, Courtney R, Warner TT, Holton JL (2018) A Histologic study of the circadian system in parkinson disease, multiple system atrophy, and progressive supranuclear palsy. JAMA Neurol 75(8):1008–1012PubMedPubMedCentralCrossRef

Galbiati A, Verga L, Giora E, Zucconi M, Ferini-Strambi L (2018) The risk of neurodegeneration in REM sleep behavior disorder: a systematic review and meta-analysis of longitudinal studies. Sleep Med Rev 43:37–46PubMedCrossRef

Gallea C, Ewenczyk C, Degos B, Welter ML, Grabli D, Leu-Semenescu S, Valabregue R, Berroir P, Yahia-Cherif L, Bertasi E, Fernandez-Vidal S, Bardinet E, Roze E, Benali H, Poupon C, François C, Arnulf I, Lehéricy S, Vidailhet M (2017) Pedunculopontine network dysfunction in Parkinson’s disease with postural control and sleep disorders. Mov Disord 32(5):693–704PubMedCrossRef

Garcia-Borreguero D, Silber MH, Winkelman JW, Högl B, Bainbridge J, Buchfuhrer M, Hadjigeorgiou G, Inoue Y, Manconi M, Oertel W, Ondo W, Winkelmann J, Allen RP (2016) Guidelines for the first-line treatment of restless legs syndrome/Willis–Ekbom disease, prevention and treatment of dopaminergic augmentation: a combined task force of the IRLSSG, EURLSSG, and the RLS-foundation. Sleep Med 21:1–11PubMedCrossRef

Gjerstad MD, Wentzel-Larsen T, Aarsland D, Larsen JP (2007) Insomnia in Parkinson’s disease: frequency and progression over time. J Neurol Neurosurg Psychiatry 78(5):476–479PubMedCrossRef

Gjerstad MD, Tysnes OB, Larsen JP (2011) Increased risk of leg motor restlessness but not RLS in early Parkinson disease. Neurology 77(22):1941–1946PubMedCrossRef

Hackius M, Werth E, Sürücü O, Baumann CR, Imbach LL (2016) Electrophysiological evidence for alternative motor networks in REM sleep behavior disorder. J Neurosci 36(46):11795–11800PubMedPubMedCentralCrossRef

Haschka D, Volani C, Stefani A, Tymoszuk P, Mitterling T, Holzknecht E, Heidbreder A, Coassin S, Sumbalova Z, Seifert M, Dichtl S, Theurl I, Gnaiger E, Kronenberg F, Frauscher B, Högl B, Weiss G (2019) Association of mitochondrial iron deficiency and dysfunction with idiopathic restless legs syndrome. Mov Disord 34(1):114–123PubMedCrossRef

Högl B, Stefani A, Videnovic A (2018) Idiopathic REM sleep behaviour disorder and neurodegeneration— an update. Nat Rev Neurol 14(1):40–55PubMedCrossRef

Humbert M, Findley J, Hernandez-Con M, Chahine LM (2017) Cognitive behavioral therapy for insomnia in Parkinson’s disease: a case series. NPJ Parkinsons Dis 3:25PubMedPubMedCentralCrossRef

Iranzo A, Tolosa E, Gelpi E, Molinuevo JL, Valldeoriola F, Serradell M, Sanchez-Valle R, Vilaseca I, Lomeña F, Vilas D, Lladó A, Gaig C, Santamaria J (2013) Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study. Lancet Neurol 12(5):443–453PubMedCrossRef

Iranzo A, Fernández-Arcos A, Tolosa E, Serradell M, Molinuevo JL, Valldeoriola F, Gelpi E, Vilaseca I, Sánchez-Valle R, Lladó A, Gaig C, Santamaría J (2014) Neurodegenerative disorder risk in idiopathic REM sleep behavior disorder: study in 174 patients. PLoS ONE 9(2):e89741PubMedPubMedCentralCrossRef

Jozwiak N, Postuma RB, Montplaisir J, Latreille V, Panisset M, Chouinard S, Bourgouin PA, Gagnon JF (2017) REM sleep behavior disorder and cognitive impairment in Parkinson's disease. Sleep. https://doi.org/10.1093/sleep/zsx101 PubMedPubMedCentralCrossRef

Kedia S, Moro E, Tagliati M, Lang AE, Kumar R (2004) Emergence of restless legs syndrome during subthalamic stimulation for Parkinson disease. Neurology 63(12):2410–2412PubMedCrossRef

Lees AJ, Blackburn NA, Campbell VL (1988) The nighttime problems of Parkinson’s disease. Clin Neuropharmacol 11:512–519PubMedCrossRef

Mantovani S, Smith SS, Gordon R, O’Sullivan JD (2018) An overview of sleep and circadian dysfunction in Parkinson’s disease. J Sleep Res 27(3):e12673PubMedCrossRef

Marinus J, Visser M, van Hilten JJ, Lammers GJ, Stiggelbout AM (2003) Assessment of sleep and sleepiness in Parkinson disease. Sleep 26:1049–1054PubMedCrossRef

McGrane IR, Leung JG, St Louis EK, Boeve BF (2015) Melatonin therapy for REM sleep behavior disorder: a critical review of evidence. Sleep Med 16(1):19–26PubMedCrossRef

Musiek ES, Holtzman DM (2016) Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science 354(6315):1004–1008PubMedPubMedCentralCrossRef

Neikrug AB, Ancoli-Israel S (2012) Diagnostic tools for REM sleep behavior disorder. Sleep Med Rev 16(5):415–429PubMedCrossRef

Ohayon MM, Schenck CH (2010) Violent behavior during sleep: prevalence, comorbidity and consequences. Sleep Med 11(9):941–946PubMedPubMedCentralCrossRef

Ortuño-Lizarán I, Esquiva G, Beach TG, Serrano GE, Adler CH, Lax P, Cuenca N (2018) Degeneration of human photosensitive retinal ganglion cells may explain sleep and circadian rhythms disorders in Parkinson’s disease. Acta Neuropathol Commun 6(1):90PubMedPubMedCentralCrossRef

Pagano G, De Micco R, Yousaf T, Wilson H, Chandra A, Politis M (2018) REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. Neurology 91(10):e894–e905PubMedCrossRef

Patel S, Ojo O, Genc G, Oravivattanakul S, Huo Y, Rasameesoraj T, Wang L, Bena J, Drerup M, Foldvary-Schaefer N, Ahmed A, Fernandez HH (2017) A computerized cognitive behavioral therapy randomized, controlled, pilot trial for insomnia in parkinson disease (ACCORD-PD). J Clin Mov Disord 4:16PubMedPubMedCentralCrossRef

Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, Ziemssen T (2012a) Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 27(5):617–626PubMedCrossRef

Postuma RB, Arnulf I, Hogl B, Iranzo A, Miyamoto T, Dauvilliers Y, Oertel W, Ju YE, Puligheddu M, Jennum P, Pelletier A, Wolfson C, Leu-Semenescu S, Frauscher B, Miyamoto M, Cochen De Cock V, Unger MM, Stiasny-Kolster K, Fantini ML, Montplaisir JY (2012b) A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov Disord 27(7):913–916PubMedPubMedCentralCrossRef

Postuma RB, Iranzo A, Hogl B, Arnulf I, Ferini-Strambi L, Manni R, Miyamoto T, Oertel W, Dauvilliers Y, Ju YE, Puligheddu M, Sonka K, Pelletier A, Santamaria J, Frauscher B, Leu-Semenescu S, Zucconi M, Terzaghi M, Miyamoto M, Unger MM, Carlander B, Fantini ML, Montplaisir JY (2015) Risk factors for neurodegeneration in idiopathic rapid eye movement sleep behavior disorder: a multicenter study. Ann Neurol 77(5):830–839PubMedPubMedCentralCrossRef

Rios Romenets S, Creti L, Fichten C, Bailes S, Libman E, Pelletier A, Postuma RB (2013) Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease—a randomized study. Parkinsonism Relat Disord 19(7):670–675PubMedCrossRef

Rodrigues TM, Castro Caldas A, Ferreira JJ (2016) Pharmacological interventions for daytime sleepiness and sleep disorders in Parkinson’s disease: systematic review and meta-analysis. Parkinsonism Relat Disord 27:25–34PubMedCrossRef

Schenck CH, Bundlie SR, Mahowald MW (1996) Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46(2):388–393PubMedCrossRef

Schenck CH, Montplaisir JY, Frauscher B, Hogl B, Gagnon JF, Postuma R, Sonka K, Jennum P, Partinen M, Arnulf I, Cochen de Cock V, Dauvilliers Y, Luppi PH, Heidbreder A, Mayer G, Sixel-Döring F, Trenkwalder C, Unger M, Young P, Wing YK, Ferini-Strambi L, Ferri R, Plazzi G, Zucconi M, Inoue Y, Iranzo A, Santamaria J, Bassetti C, Möller JC, Boeve BF, Lai YY, Pavlova M, Saper C, Schmidt P, Siegel JM, Singer C, St Louis E, Videnovic A, Oertel W (2013) Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy—a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group. Sleep Med 14(8):795–806PubMedCrossRefPubMedCentral

Schrempf W, Fauser M, Wienecke M, Brown S, Maaß A, Ossig C, Otto K, Brandt MD, Löhle M, Schwanebeck U, Graehlert X, Reichmann H, Storch A (2018) Rasagiline improves polysomnographic sleep parameters in patients with Parkinson’s disease: a double-blind, baseline-controlled trial. Eur J Neurol 25(4):672–679PubMedCrossRef

Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The Movement disorder society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S42–S80PubMedPubMedCentralCrossRef

Sharma VD, Sengupta S, Chitnis S, Amara AW (2018) Deep brain stimulation and sleep–wake disturbances in parkinson disease: a review. Front Neurol 27(9):697CrossRef

Thannickal TC, Lai YY, Siegel JM (2007) Hypocretin (orexin) cell loss in Parkinson’s disease. Brain 130(Pt 6):1586–1595PubMedCrossRef

Tholfsen LK, Larsen JP, Schulz J, Tysnes OB, Gjerstad MD (2017) Changes in insomnia subtypes in early Parkinson disease. Neurology 88(4):352–358PubMedCrossRef

Trenkwalder C, Kies B, Rudzinska M, Fine J, Nikl J, Honczarenko K, Dioszeghy P, Hill D, Anderson T, Myllyla V, Kassubek J, Steiger M, Zucconi M, Tolosa E, Poewe W, Surmann E, Whitesides J, Boroojerdi B, Chaudhuri KR, Recover Study Group (2011a) Rotigotine effects on early morning motor function and sleep in Parkinson’s disease: a double-blind, randomized, placebo-controlled study (RECOVER). Mov Disord 26(1):90–99PubMedCrossRef

Trenkwalder C, Kohnen R, Högl B, Metta V, Sixel-Döring F, Frauscher B, Hülsmann J, Martinez-Martin P, Chaudhuri KR (2011b) Parkinson’s disease sleep scale—validation of the revised version PDSS-2. Mov Disord 26:644–652PubMedCrossRef

Valadas JS, Esposito G, Vandekerkhove D, Miskiewicz K, Deaulmerie L, Raitano S, Seibler P, Klein C, Verstreken P (2018) ER lipid defects in neuropeptidergic neurons impair sleep patterns in Parkinson’s disease. Neuron 98(6):1155–1169.e6PubMedCrossRef

Valencia Garcia S, Libourel PA, Lazarus M, Grassi D, Luppi PH, Fort P (2017) Genetic inactivation of glutamate neurons in the rat sublaterodorsal tegmental nucleus recapitulates REM sleep behaviour disorder. Brain 140(2):414–428PubMedCrossRef

Valko PO, Waldvogel D, Weller M, Bassetti CL, Held U, Baumann CR (2010) Fatigue and excessive daytime sleepiness in idiopathic Parkinson’s disease differently correlate with motor symptoms, depression and dopaminergic treatment. Eur J Neurol 17(12):1428–1436PubMedCrossRef

Verbaan D, van Rooden SM, van Hilten JJ, Rijsman RM (2010) Prevalence and clinical profile of restless legs syndrome in Parkinson’s disease. Mov Disord 25(13):2142–2147PubMedCrossRef

Videnovic A, Noble C, Reid KJ, Peng J, Turek FW, Marconi A, Rademaker AW, Simuni T, Zadikoff C, Zee PC (2014) Circadian melatonin rhythm and excessive daytime sleepiness in Parkinson disease. JAMA Neurol 71(4):463–469PubMedPubMedCentralCrossRef

Videnovic A, Klerman EB, Wang W, Marconi A, Kuhta T, Zee PC (2017) Timed light therapy for sleep and daytime sleepiness associated With Parkinson disease: a randomized clinical trial. JAMA Neurol 74(4):411–418PubMedPubMedCentralCrossRef

Ylikoski A, Martikainen K, Sieminski M, Partinen M (2015) Parkinson’s disease and insomnia. Neurol Sci 36(11):2003–2010PubMedCrossRef

Titel: Sleep–wake and circadian disturbances in Parkinson disease: a short clinical guide
verfasst von: Christian R. Baumann
Publikationsdatum: 29.06.2019
Verlag: Springer Vienna
Erschienen in: Journal of Neural Transmission / Ausgabe 7/2019
Print ISSN: 0300-9564
Elektronische ISSN: 1435-1463
DOI: https://doi.org/10.1007/s00702-019-02039-3

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders gilt das offenbar für weibliche Kranke, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 7/2019

Neuropsychiatric aspects of Parkinson’s disease

Dynamics of device-based treatments for Parkinson’s disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa–carbidopa intestinal gel, and deep brain stimulation

α-Synuclein in Parkinson’s disease: causal or bystander?

Polypharmacy in Parkinson’s disease: risks and benefits with little evidence

Time for a new definition of Parkinson’s disease